Prosecution Insights
Prosecution Insights
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (25%) |
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGOPIAN, CASEY SHEA | 1 | 54.3% | +33.4% |
| LI, RUIXIANG | 1 | 59.4% | +19.1% |
| CLOW, LORI A | 1 | 63.9% | +28.8% |
| LEVERETT, MARY CHANG | 1 | 61.1% | +22.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17425384 | NOVEL BIOMARKERS AND DIAGNOSTIC PROFILES FOR PROSTATE CANCER | CLOW, LORI A | 66d overdue |
| 17046829 | CLASSIFICATION AND PROGNOSIS OF PROSTATE CANCER | LEVERETT, MARY CHANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17441849 | PHOTOACTIVE ANTIBODIES | LI, RUIXIANG | 98d overdue |
| 17425384 | NOVEL BIOMARKERS AND DIAGNOSTIC PROFILES FOR PROSTATE CANCER | CLOW, LORI A | 66d overdue |
| 17928037 | A METHOD OF COATING AN OCULAR PROSTHETIC DEVICE AND OTHER PROSTHETICS | HAGOPIAN, CASEY SHEA | 34d |
| 17046829 | CLASSIFICATION AND PROGNOSIS OF PROSTATE CANCER | LEVERETT, MARY CHANG | — |
| Art Unit | Apps |
|---|---|
| 1687 | 2 |
| 1617 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17928037 | A METHOD OF COATING AN OCULAR PROSTHETIC DEVICE AND OTHER PROSTHETICS | HAGOPIAN, CASEY SHEA | 1617 | §103 | Non-Final OA | 34d | Pending | Nov 28, 2022 |
| 17441849 | PHOTOACTIVE ANTIBODIES | LI, RUIXIANG | 1674 | §112 | Final Rejection | 98d overdue | Pending | Sep 22, 2021 |
| 17425384 | NOVEL BIOMARKERS AND DIAGNOSTIC PROFILES FOR PROSTATE CANCER | CLOW, LORI A | 1687 | §101§103§112 | Non-Final OA | 66d overdue | Pending | Jul 23, 2021 |
| 17046829 | CLASSIFICATION AND PROGNOSIS OF PROSTATE CANCER | LEVERETT, MARY CHANG | 1687 | §101 | Final Rejection | — | Pending | Oct 12, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial